Durham, United States
Ten63 Therapeutics, founded in 2018 and based in the United States, is at the forefront of the Biotechnology, Health Care, and Pharmaceutical industries. The company is committed to revolutionizing human health by developing therapeutics that target cancer and other severe diseases. Utilizing their proprietary in silico platform BEYOND, Ten63 Therapeutics aims to address previously undruggable targets and integrate durable response strategies into drug design from the outset.
In their pursuit of innovation, Ten63 emphasizes values such as passion, teamwork, and creative problem-solving. Their inclusive culture welcomes diverse talents to join their mission in making the world healthier.
Recently, Ten63 secured a $15.90M Series A investment on 02 May 2023, spearheaded by investors like Morpheus Ventures, SOSV, Draper Associates, Hatteras Venture Partners, Alexandria Venture Investments, and Sigma Group. This financial backing underscores the confidence stakeholders have in Ten63's innovative approach and potential market impact.
